Corcept Therapeutics Inc

HTD

Company Profile

  • Business description

    Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

  • Contact

    101 Redwood Shores Parkway
    Redwood CityCA94065
    USA

    T: +1 650 327-3270

    E: [email protected]

    https://www.corcept.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    730

Stocks News & Analysis

stocks

Nvidia earnings: Business as usual as forecasts suggest that all is well

Are the shares cheap?
stocks

Why don’t good returns guarantee a 5-star rating?

Amy Arnott explains how Morningstar’s stock ratings work.
stocks

Despite post earnings rally ASX share still cheap

Lifting our 2028 earnings estimate by 20%.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,932.4064.90-0.72%
CAC 408,218.621.840.02%
DAX 4026,089.0143.640.17%
Dow JONES (US)50,759.42848.75-1.64%
FTSE 10010,661.0528.82-0.27%
HKSE23,294.75213.42-0.91%
NASDAQ24,328.38181.38-0.74%
Nikkei 22559,024.28163.850.28%
NZX 50 Index14,264.2942.67-0.30%
S&P 5007,340.5376.06-1.03%
S&P/ASX 2008,821.8061.40-0.69%
SSE Composite Index3,587.833.250.09%

Market Movers